Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Ophthalmology

  Free Subscription


Articles published in J Ocul Pharmacol Ther

Retrieve available abstracts of 121 articles:
HTML format



Single Articles


    May 2022
  1. LOBERG LI, Henriques TA, Johnson JK, Miller PE, et al
    Characterization and Potential Mitigation of Corneal Effects in Nonclinical Toxicology Studies in Animals Administered Depatuxizumab Mafodotin.
    J Ocul Pharmacol Ther. 2022 May 10. doi: 10.1089/jop.2022.0006.
    PubMed     Abstract available


  2. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2022;38:269-270.
    PubMed    


    April 2022
  3. CHOUDHARY M, Ildefonso CJ, Lewin AS, Malek G, et al
    Gene Delivery of a Caspase Activation and Recruitment Domain Improves Retinal Pigment Epithelial Function and Modulates Inflammation in a Mouse Model with Features of Dry Age-Related Macular Degeneration.
    J Ocul Pharmacol Ther. 2022 Apr 19. doi: 10.1089/jop.2022.0002.
    PubMed     Abstract available


  4. FOGAGNOLO P, Romano D, De Ruvo V, Sabella P, et al
    Clinical Efficacy of an Eyedrop Containing Hyaluronic Acid and Ginkgo Biloba in the Management of Dry Eye Disease Induced by Cataract Surgery.
    J Ocul Pharmacol Ther. 2022 Apr 18. doi: 10.1089/jop.2021.0123.
    PubMed     Abstract available


  5. GHOSN C, Rajagopalan L, Ugarte S, Mistry S, et al
    Intraocular Pressure-Lowering Efficacy of a Sustained-Release Bimatoprost Implant in Dog Eyes Pretreated with Selective Laser Trabeculoplasty.
    J Ocul Pharmacol Ther. 2022 Apr 18. doi: 10.1089/jop.2021.0104.
    PubMed     Abstract available


  6. KUTLUTURK G, Altan C, Yasar T
    Effects of Topical Antiglaucomatous Medications on Conjunctival Thickness: A Prospective Anterior Segment Optical Coherence Tomography Study.
    J Ocul Pharmacol Ther. 2022 Apr 11. doi: 10.1089/jop.2021.0105.
    PubMed     Abstract available


  7. MUYA L, Kansara V, Cavet ME, Ciulla T, et al
    Suprachoroidal Injection of Triamcinolone Acetonide Suspension: Ocular Pharmacokinetics and Distribution in Rabbits Demonstrates High and Durable Levels in the Chorioretina.
    J Ocul Pharmacol Ther. 2022 Apr 11. doi: 10.1089/jop.2021.0090.
    PubMed     Abstract available


  8. GHOSH AK, Bacellar-Galdino M, Iqbal S, Pappenhagen NE, et al
    Topical Porphyrin Antioxidant Protects Against Ocular Surface Pathology in a Novel Rabbit Model for Particulate Matter-Induced Dry Eye Disease.
    J Ocul Pharmacol Ther. 2022 Apr 4. doi: 10.1089/jop.2021.0131.
    PubMed     Abstract available


  9. OSORNO LL, Mosley RJ, Poley PL, Bowers J, et al
    Sustained Release of Antibody-Conjugated DNA Nanocarriers from a Novel Injectable Hydrogel for Targeted Cell Depletion to Treat Cataract Posterior Capsule Opacification.
    J Ocul Pharmacol Ther. 2022 Apr 4. doi: 10.1089/jop.2021.0111.
    PubMed     Abstract available


  10. STONEX T, Salmon JH, Adler KB, Gilger BC, et al
    Peptide Inhibitors of MARCKS Suppress Endotoxin Induced Uveitis in Rats.
    J Ocul Pharmacol Ther. 2022;38:223-231.
    PubMed     Abstract available


  11. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2022;38:201-202.
    PubMed    


    March 2022
  12. LELYTE I, Ahmed Z, Kaja S, Kalesnykas G, et al
    Structure-Function Relationships in the Rodent Streptozotocin-Induced Model for Diabetic Retinopathy: A Systematic Review.
    J Ocul Pharmacol Ther. 2022 Mar 22. doi: 10.1089/jop.2021.0128.
    PubMed     Abstract available


  13. ZHANG E, Gupta S, Olson E, Sinha PR, et al
    Effects of Regular/Dilute Proparacaine Anesthetic Eye Drops in Combination with Ophthalmic Antibiotics on Corneal Wound Healing.
    J Ocul Pharmacol Ther. 2022 Mar 11. doi: 10.1089/jop.2021.0116.
    PubMed     Abstract available


  14. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2022;38:123-124.
    PubMed    


  15. LIAO CH, Tseng CL, Lin SL, Liang CL, et al
    MicroRNA Therapy for Dry Eye Disease.
    J Ocul Pharmacol Ther. 2022;38:125-132.
    PubMed     Abstract available


    February 2022
  16. GARCIA-MEDINA JJ, Benitez-Del-Castillo J, Rodriguez-Agirretxe I, Lopez-Lopez F, et al
    Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain.
    J Ocul Pharmacol Ther. 2022 Feb 28. doi: 10.1089/jop.2021.0099.
    PubMed     Abstract available


  17. WIRTA DL, Kuwayama Y, Lu F, Shao H, et al
    Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study.
    J Ocul Pharmacol Ther. 2022 Feb 15. doi: 10.1089/jop.2021.0077.
    PubMed     Abstract available


  18. GUPTA S, Shyamsundar K, Agrawal M, Vichare N, et al
    Current Knowledge of Biologics in Treatment of Noninfectious Uveitis.
    J Ocul Pharmacol Ther. 2022 Feb 8. doi: 10.1089/jop.2021.0098.
    PubMed     Abstract available


  19. KIM JH, Kim JW, Kim CG
    Difference Between the Incidence of Retinal Fluid Subtypes and Their Association with Visual Outcomes According to the Types of Macular Neovascularization in a Korean Population.
    J Ocul Pharmacol Ther. 2022 Feb 3. doi: 10.1089/jop.2021.0103.
    PubMed     Abstract available


    January 2022
  20. HUANG HM, Kuo HK, Chiang WY, Wu PC, et al
    Combination Therapy with Intravitreal Triamcinolone Acetonide and Oral Levodopa for the Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy: A Pilot Study.
    J Ocul Pharmacol Ther. 2022 Jan 19. doi: 10.1089/jop.2021.0081.
    PubMed     Abstract available


  21. ZHANG Q, Zhang H, Qin G, Wu Y, et al
    Impact of Diquafosol Ophthalmic Solution on Tear Film and Dry Eye Symptom in Type 2 Diabetic Dry Eye: A Pilot Study.
    J Ocul Pharmacol Ther. 2022 Jan 19. doi: 10.1089/jop.2021.0083.
    PubMed     Abstract available


  22. RAJ SINGH TR
    Call for Special Issue Papers: Ocular Drug Delivery Technology Special Issue.
    J Ocul Pharmacol Ther. 2022;38:122.
    PubMed    


  23. MAHON N, Slater K, O'Brien J, Alvarez Y, et al
    Discovery and Development of the Quininib Series of Ocular Drugs.
    J Ocul Pharmacol Ther. 2022;38:33-42.
    PubMed     Abstract available


  24. HUANG W, Huang L, Li W, Saglam MS, et al
    Once-Daily Topical Phosphosulindac Is Efficacious in the Treatment of Dry Eye Disease: Studies in Rabbit Models of Its Main Clinical Subtypes.
    J Ocul Pharmacol Ther. 2022;38:102-113.
    PubMed     Abstract available


  25. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2022;38:1-2.
    PubMed    


    December 2021
  26. BEHERA G, Nagaraj GA, Thirunavukarasu SC, Jayaraman R, et al
    Effect of Blood Pressure Reduction on Intraocular Pressure and Ophthalmic Artery Blood Flow Velocity in Hypertension.
    J Ocul Pharmacol Ther. 2021 Dec 29. doi: 10.1089/jop.2021.0096.
    PubMed     Abstract available


  27. LIMON U, Sezgin Akcay BI
    Add-On Effect of Simultaneous Intravitreal Dexamethasone to Intravitreal Bevacizumab in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion.
    J Ocul Pharmacol Ther. 2021 Dec 29. doi: 10.1089/jop.2021.0100.
    PubMed     Abstract available


  28. ARAD D, Komoron S, Pe'er O, Sebbag L, et al
    Mucoadhesive Polymers Enhance Ocular Drug Delivery: Proof of Concept Study with 0.5% Tropicamide in Dogs.
    J Ocul Pharmacol Ther. 2021 Dec 28. doi: 10.1089/jop.2021.0091.
    PubMed     Abstract available


  29. YANG L, Yu P, Chen M, Lei B, et al
    Mammalian Target of Rapamycin Inhibitor Rapamycin Alleviates 7-Ketocholesterol Induced Inflammatory Responses and Vascular Endothelial Growth Factor Elevation by Regulating MAPK Pathway in Human Retinal Pigment Epithelium Cells.
    J Ocul Pharmacol Ther. 2021 Dec 21. doi: 10.1089/jop.2021.0082.
    PubMed     Abstract available


  30. FUKUDA M, Takeda N, Ishida H, Seki Y, et al
    Benzalkonium Chloride-Induced Corneal Epithelial Injury in Rabbit Reduced by Rebamipide.
    J Ocul Pharmacol Ther. 2021 Dec 21. doi: 10.1089/jop.2021.0052.
    PubMed     Abstract available


  31. ARENDT NIELSEN T, Sega R, Uggerhoj Andersen C, Vorum H, et al
    Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy.
    J Ocul Pharmacol Ther. 2021 Dec 16. doi: 10.1089/jop.2021.0055.
    PubMed     Abstract available


  32. KARAMI TK, Hailu S, Feng S, Graham R, et al
    Eyes on Lipinski's Rule of Five: A New "Rule of Thumb" for Physicochemical Design Space of Ophthalmic Drugs.
    J Ocul Pharmacol Ther. 2021 Dec 14. doi: 10.1089/jop.2021.0069.
    PubMed     Abstract available


  33. TISI A, Zerti D, Genitti G, Vicentini MT, et al
    Characterization of SARS-CoV-2 Entry Factors' Expression in Corneal and Limbal Tissues of Adult Human Donors Aged from 58 to 85.
    J Ocul Pharmacol Ther. 2021 Dec 7. doi: 10.1089/jop.2021.0085.
    PubMed     Abstract available


  34. RAJ SINGH TR
    Call for Special Issue Papers: Ocular Drug Delivery Technology Special Issue.
    J Ocul Pharmacol Ther. 2021;37:597.
    PubMed    


  35. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2021;37:543-544.
    PubMed    


  36. BUTOVICH IA, Yuksel S, Leonard B, Gadek T, et al
    Novel Lipids of the Rabbit Harderian Gland Improve Tear Stability in an Animal Model of Dry Eye Disease.
    J Ocul Pharmacol Ther. 2021;37:545-555.
    PubMed     Abstract available


    November 2021
  37. CHALIMESWAMY A, Thanuja MY, Ranganath SH, Pandya K, et al
    Oxidative Stress Induces a Breakdown of the Cytoskeleton and Tight Junctions of the Corneal Endothelial Cells.
    J Ocul Pharmacol Ther. 2021 Nov 23. doi: 10.1089/jop.2021.0037.
    PubMed     Abstract available


  38. LANDOWSKI M, Bowes Rickman C
    Targeting Lipid Metabolism for the Treatment of Age-Related Macular Degeneration: Insights from Preclinical Mouse Models.
    J Ocul Pharmacol Ther. 2021 Nov 17. doi: 10.1089/jop.2021.0067.
    PubMed     Abstract available


  39. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2021;37:493-494.
    PubMed    


  40. MANO F, Sakata S, Chang KC, Mano T, et al
    Effects of Zinc Acetate Hydrate Treatment on Serum Oxidative Stress Markers in Patients with Macular Drusen.
    J Ocul Pharmacol Ther. 2021;37:518-524.
    PubMed     Abstract available


  41. LAKSMITA YA, Sidik M, Siregar NC, Nusanti S, et al
    Neuroprotective Effects of Citicoline on Methanol-Intoxicated Retina Model in Rats.
    J Ocul Pharmacol Ther. 2021;37:534-541.
    PubMed     Abstract available


    October 2021
  42. CHEN L, Qu L, Gui Q, Wang S, et al
    Effects of Anti-Vascular Endothelial Growth Factor Drugs Before and After Pars Plana Vitrectomy in Patients with Polypoidal Choroidal Vasculopathy and Vitreous Hemorrhage.
    J Ocul Pharmacol Ther. 2021 Oct 22. doi: 10.1089/jop.2021.0039.
    PubMed     Abstract available


  43. SHELLEY H, Annaji M, Smith FT, Babu RJ, et al
    Difluprednate-Hydroxypropyl-beta-Cyclodextrin-Based Ophthalmic Solution for Improved Delivery in a Porcine Eye Model.
    J Ocul Pharmacol Ther. 2021 Oct 18. doi: 10.1089/jop.2021.0073.
    PubMed     Abstract available


  44. LIMON U, Sezgin Akcay BI
    Efficacy of Intravitreal Dexamethasone After Combined Phacoemulsification and Pars Plana Vitrectomy for Diabetic Tractional Retinal Detachments.
    J Ocul Pharmacol Ther. 2021 Oct 15. doi: 10.1089/jop.2021.0072.
    PubMed     Abstract available


  45. SARIGUL SEZENOZ A, Akkoyun I, Helvacioglu F, Haberal N, et al
    Antiproliferative and Mitochondrial Protective Effects of Apigenin in an Oxygen-Induced Retinopathy In Vivo Mouse Model.
    J Ocul Pharmacol Ther. 2021 Oct 15. doi: 10.1089/jop.2021.0046.
    PubMed     Abstract available


  46. TADEPALLI S, Farhath HP, Sudhir RR, Padmanabhan P, et al
    Reliability of Aqueous Flare Measurements During Uveitis by a Spot Fluorometer.
    J Ocul Pharmacol Ther. 2021 Oct 13. doi: 10.1089/jop.2021.0053.
    PubMed     Abstract available


  47. WU JH, Wang TH, Huang JY, Su CC, et al
    Ocular Surface Disease in Glaucoma Patients Randomized to Benzalkonium Chloride-Containing Latanoprost and Preservative-Free Bimatoprost.
    J Ocul Pharmacol Ther. 2021 Oct 4. doi: 10.1089/jop.2021.0071.
    PubMed     Abstract available


  48. KOLLI A, Toris CB, Reed DM, Gilbert J, et al
    The Effects of Topical Timolol and Latanoprost on Calculated Ocular Perfusion Pressure in Nonglaucomatous Volunteers.
    J Ocul Pharmacol Ther. 2021 Oct 4. doi: 10.1089/jop.2021.0068.
    PubMed     Abstract available


  49. HAN IC, Burnight ER, Kaalberg EE, Boyce TM, et al
    Chimeric Helper-Dependent Adenoviruses Transduce Retinal Ganglion Cells and Muller Cells in Human Retinal Explants.
    J Ocul Pharmacol Ther. 2021 Oct 1. doi: 10.1089/jop.2021.0057.
    PubMed     Abstract available


  50. KIM J, Moon TK, Yoon HJ, Ji YS, et al
    Efficacy of Switching from Cyclosporine A 0.05% Anionic Emulsion to Cyclosporine A 0.1% Cationic Emulsion in Patients with Dry Eye Associated with Sjogren's Syndrome.
    J Ocul Pharmacol Ther. 2021;37:472-478.
    PubMed     Abstract available


  51. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2021;37:439-440.
    PubMed    


  52. RASTMANESH R
    Aquaporin5-Targeted Treatment for Dry Eye Through Bioactive Compounds and Gut Microbiota.
    J Ocul Pharmacol Ther. 2021;37:464-471.
    PubMed     Abstract available


  53. HOANG C, Nguyen AK, Nguyen TQ, Fang W, et al
    Application of Dimethyl Sulfoxide as a Therapeutic Agent and Drug Vehicle for Eye Diseases.
    J Ocul Pharmacol Ther. 2021;37:441-451.
    PubMed     Abstract available


    September 2021
  54. KIM JH, Kim JW, Kim CG
    Five-Year Reactivation After Ranibizumab or Aflibercept Treatment for Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy.
    J Ocul Pharmacol Ther. 2021 Sep 14. doi: 10.1089/jop.2021.0051.
    PubMed     Abstract available


  55. NERI P, Pichi F
    SARS-CoV-2 and the Eye: The Pandora's Box of Ocular Immunology.
    J Ocul Pharmacol Ther. 2021 Sep 9. doi: 10.1089/jop.2021.0058.
    PubMed     Abstract available


  56. SANDER BP
    Prevention of Choroidal Thinning by 0.01% Atropine Administered 24 h Before Exposure to Hyperopic Blur in Young Myopes.
    J Ocul Pharmacol Ther. 2021 Sep 3. doi: 10.1089/jop.2021.0006.
    PubMed     Abstract available


  57. ZARBIN MA, Novack G
    N-of-1 Clinical Trials: A Scientific Approach to Personalized Medicine for Patients with Rare Retinal Diseases Such as Retinitis Pigmentosa.
    J Ocul Pharmacol Ther. 2021 Sep 3. doi: 10.1089/jop.2021.0059.
    PubMed     Abstract available


  58. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2021;37:383-385.
    PubMed    


  59. YAO X, Chen C, Zhang J, Xu Y, et al
    Novel Peptide NT/K-CRS Derived from Kringle Structure of Neurotrypsin Inhibits Neovascularization In Vitro and In Vivo.
    J Ocul Pharmacol Ther. 2021;37:412-420.
    PubMed     Abstract available


  60. PARK SA, Good KL, Thomasy SM, Kass PH, et al
    Effect of Withdrawing Chronic Topical Immune Modulating Treatment on Schirmer Tear Test Values in Dogs with Dry Eye Disease: Relevance to Dry Eye Studies.
    J Ocul Pharmacol Ther. 2021;37:394-398.
    PubMed     Abstract available


  61. HERNANDEZ E, Taisne C, Lussignol M, Esclatine A, et al
    Commercially Available Eye Drops Containing Trehalose Protect Against Dry Conditions via Autophagy Induction.
    J Ocul Pharmacol Ther. 2021;37:386-393.
    PubMed     Abstract available


    August 2021
  62. GANGE WS, Qiao JB, Park PJ, McDonnell JF, et al
    Protection of Retinal Function by Nucleoside Reverse Transcriptase Inhibitors Following Retinal Ischemia/Reperfusion Injury.
    J Ocul Pharmacol Ther. 2021 Aug 26. doi: 10.1089/jop.2020.0083.
    PubMed     Abstract available


  63. SHARMA B, Soni D, Mohan RR, Sarkar D, et al
    Corticosteroids in the Management of Infectious Keratitis: A Concise Review.
    J Ocul Pharmacol Ther. 2021 Aug 26. doi: 10.1089/jop.2021.0040.
    PubMed     Abstract available


  64. GONZALEZ-SALINAS R, Yeu E, Holdbrook M, Baba SN, et al
    Collarette Elimination and Demodex Mite Eradication with Topical Lotilaner Ophthalmic Solution, 0.25.
    J Ocul Pharmacol Ther. 2021 Aug 20. doi: 10.1089/jop.2021.0011.
    PubMed     Abstract available


    July 2021
  65. THANUJA MY, Suma BS, Dinesh D, Ranganath SH, et al
    Microtubule Stabilization Protects Hypothermia-Induced Damage to the Cytoskeleton and Barrier Integrity of the Corneal Endothelial Cells.
    J Ocul Pharmacol Ther. 2021 Jul 2. doi: 10.1089/jop.2021.0036.
    PubMed     Abstract available


  66. HUANG W, Wen Z, Saglam MS, Huang L, et al
    Phospho-Sulindac (OXT-328) Inhibits Dry Eye Disease in Rabbits: A Dose-, Formulation- and Structure-Dependent Effect.
    J Ocul Pharmacol Ther. 2021;37:321-330.
    PubMed     Abstract available


  67. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2021;37:319-320.
    PubMed    


  68. GAO X, Xiang Q, Fang J
    The Effect of Oral Vitamin A Supplementation on Chalazion in Young Children with Vitamin A Deficiency: A Pilot Study.
    J Ocul Pharmacol Ther. 2021;37:354-359.
    PubMed     Abstract available


  69. FRIDMAN G, Sadlak N, Eliassi-Rad B, Desai MA, et al
    Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital.
    J Ocul Pharmacol Ther. 2021;37:338-342.
    PubMed     Abstract available


  70. ALSAIF A, Karam M, Al-Naseem A, Almuhanna A, et al
    Diclofenac Versus Dexamethasone Following Strabismus Surgery: A Systematic Review and Meta-Analysis.
    J Ocul Pharmacol Ther. 2021;37:343-353.
    PubMed     Abstract available


    June 2021
  71. SABANER MC, Dogan M, Akdogan M, Karadag S, et al
    Evaluation of Retinal and Choroidal Microcirculation Alterations After a Single Dose of Oral 5-mg Tadalafil: A Prospective Pilot Optical Coherence Tomography Angiography Study.
    J Ocul Pharmacol Ther. 2021 Jun 18. doi: 10.1089/jop.2020.0124.
    PubMed     Abstract available


  72. CHEWA RAJA JS, Singh S, Ismail F
    Pre-Emptive Topical Ketorolac Tromethamine 0.5% for Panretinal Photocoagulation.
    J Ocul Pharmacol Ther. 2021;37:313-317.
    PubMed     Abstract available


  73. PAIVA MRB, Vasconcelos-Santos DV, Coelho MM, Machado RR, et al
    Licarin A as a Novel Drug for Inflammatory Eye Diseases.
    J Ocul Pharmacol Ther. 2021;37:290-300.
    PubMed     Abstract available


    May 2021
  74. HOMMER N, Schmidl D, Kallab M, Bauer M, et al
    The Effect of Orally Administered Low-Dose Dronabinol on Retinal Blood Flow and Oxygen Metabolism in Healthy Subjects.
    J Ocul Pharmacol Ther. 2021 May 17. doi: 10.1089/jop.2020.0131.
    PubMed     Abstract available


  75. QIN T, Gao S, Wang W
    Celastrol Regulates the Secretion of Interleukin-17 in Patients with Sympathetic Ophthalmia Through Signal Transducer and Activator of Transcription 3.
    J Ocul Pharmacol Ther. 2021 May 17. doi: 10.1089/jop.2020.0128.
    PubMed     Abstract available


  76. VURAL E, Hazar L
    Assessment of Inflammation Biomarkers in Diabetic Macular Edema Treated with Intravitreal Dexamethasone Implant.
    J Ocul Pharmacol Ther. 2021 May 7. doi: 10.1089/jop.2020.0130.
    PubMed     Abstract available


  77. BEESON C, Peterson YK, Perron N, Bandyopadhyay M, et al
    Newly Identified Chemicals Preserve Mitochondrial Capacity and Decelerate Loss of Photoreceptor Cells in Murine Retinal Degeneration Models.
    J Ocul Pharmacol Ther. 2021 May 4. doi: 10.1089/jop.2020.0140.
    PubMed     Abstract available


  78. NOVACK GD
    Eyes on New Product Development: Regulations, Generics, and Disruptive Technologies.
    J Ocul Pharmacol Ther. 2021;37:191-192.
    PubMed    


  79. UCAR F, Cetinkaya S
    The Results of Preoperative Use of Topical Brimonidine in Strabismus Surgery.
    J Ocul Pharmacol Ther. 2021;37:230-235.
    PubMed     Abstract available


    April 2021
  80. ANDRADE N, Crispim Ribeiro J, Silva PM, Savio D, et al
    Effect of Topical Instillation of Pegaptanib Sodium Upon Inflammatory Corneal Neovascularization in Rabbits.
    J Ocul Pharmacol Ther. 2021 Apr 22. doi: 10.1089/jop.2020.0010.
    PubMed     Abstract available


  81. GELFMAN CM, Grishanin R, Bender KO, Nguyen A, et al
    Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema.
    J Ocul Pharmacol Ther. 2021;37:181-190.
    PubMed     Abstract available


  82. SINGH RK, Binette F, Seiler M, Petersen-Jones SM, et al
    Pluripotent Stem Cell-Based Organoid Technologies for Developing Next-Generation Vision Restoration Therapies of Blindness.
    J Ocul Pharmacol Ther. 2021;37:147-156.
    PubMed     Abstract available


    March 2021
  83. ROY CHOWDHURY U, Kudgus RA, Holman BH, Rinkoski TA, et al
    Pharmacological Profile and Ocular Hypotensive Effects of Cromakalim Prodrug 1, a Novel ATP-Sensitive Potassium Channel Opener, in Normotensive Dogs and Nonhuman Primates.
    J Ocul Pharmacol Ther. 2021 Mar 30. doi: 10.1089/jop.2020.0137.
    PubMed     Abstract available


  84. ROWE-RENDLEMAN CL, Glickman R
    Regulations, Generics, and Disruptive Technologies in Ophthalmology: What Every Scientist Needs to Know.
    J Ocul Pharmacol Ther. 2021 Mar 17. doi: 10.1089/jop.2021.29078.
    PubMed    


  85. WANG RK, Jacques SL
    Innovative Optical Technologies in Ophthalmology and Eye Research.
    J Ocul Pharmacol Ther. 2021 Mar 17. doi: 10.1089/jop.2021.29077.
    PubMed    


  86. SALAS-AMBROSIO PJ, Bernad-Bernad MJ, Linares-Alba MA, Garcia-Santisteban R, et al
    Toxicity Evaluation of a Novel Rapamycin Liposomal Formulation After Subconjunctival and Intravitreal Injection.
    J Ocul Pharmacol Ther. 2021 Mar 10. doi: 10.1089/jop.2020.0108.
    PubMed     Abstract available


  87. NASONKIN IO
    Gene and Stem Cell-Based Therapies: Emerging Therapeutic Modalities in Ophthalmology.
    J Ocul Pharmacol Ther. 2021 Mar 4. doi: 10.1089/jop.2021.29076.
    PubMed    


  88. RETTINGER CL, Kaini RR, Burke TA, Wang HC, et al
    Neurotrophic Factors Secreted by Induced Pluripotent Stem Cell-Derived Retinal Progenitors Promote Retinal Survival and Preservation in an Adult Porcine Neuroretina Model.
    J Ocul Pharmacol Ther. 2021 Mar 3. doi: 10.1089/jop.2020.0088.
    PubMed     Abstract available


  89. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2021;37:73-74.
    PubMed    


  90. OLIVERIO GW, Spinella R, Postorino EI, Inferrera L, et al
    Safety and Tolerability of an Eye Drop Based on 0.6% Povidone-Iodine Nanoemulsion in Dry Eye Patients.
    J Ocul Pharmacol Ther. 2021;37:90-96.
    PubMed     Abstract available


    February 2021
  91. FUWA M, Shimazaki A, Odani-Kawabata N, Kirihara T, et al
    Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.
    J Ocul Pharmacol Ther. 2021 Feb 17. doi: 10.1089/jop.2020.0071.
    PubMed     Abstract available


  92. BASTIA E, Toris C, Bukowski JM, Brambilla S, et al
    NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys.
    J Ocul Pharmacol Ther. 2021 Feb 15. doi: 10.1089/jop.2020.0126.
    PubMed     Abstract available


  93. ARTUC T, Batur M, Seven E, Tekin S, et al
    Effectiveness of Pulmonary Surfactant in the Treatment of Corneal Edema.
    J Ocul Pharmacol Ther. 2021 Feb 8. doi: 10.1089/jop.2020.0121.
    PubMed     Abstract available


  94. QADRI A, Cai CL, Deslouches K, Siddiqui F, et al
    Ocular Versus Oral Propranolol for Prevention and/or Treatment of Oxygen-Induced Retinopathy in a Rat Model.
    J Ocul Pharmacol Ther. 2021 Feb 3. doi: 10.1089/jop.2020.0092.
    PubMed     Abstract available


  95. JIANG T, Zhang X, Zhou M, Jiang R, et al
    Prognosis of Ocular Tuberculosis Following Long-Term Antitubercular Therapy.
    J Ocul Pharmacol Ther. 2021 Feb 1. doi: 10.1089/jop.2020.0100.
    PubMed     Abstract available


    January 2021
  96. UCAN GUNDUZ G, Yalcinbayir O, Cekic S, Yildiz M, et al
    Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab.
    J Ocul Pharmacol Ther. 2021 Jan 28. doi: 10.1089/jop.2020.0081.
    PubMed     Abstract available


  97. WANG R, Xia J, Tang J, Liu D, et al
    Surface Modification of Intraocular Lens with Hydrophilic Poly(Sulfobetaine Methacrylate) Brush for Posterior Capsular Opacification Prevention.
    J Ocul Pharmacol Ther. 2021 Jan 26. doi: 10.1089/jop.2020.0134.
    PubMed     Abstract available


  98. DINC E, Ayaz L, Kurt AH, Dursun O, et al
    Effects of Bone Marrow and Adipose-Derived Mesenchymal Stem Cells on microRNA Expressions in Acute Alkaline Corneal Burn.
    J Ocul Pharmacol Ther. 2021 Jan 21. doi: 10.1089/jop.2020.0107.
    PubMed     Abstract available


  99. CLARK D, Sheppard J, Brady TC
    A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease.
    J Ocul Pharmacol Ther. 2021 Jan 15. doi: 10.1089/jop.2020.0087.
    PubMed     Abstract available


  100. TAKEDA N, Fukuda M, Sasaki H, Sugiyama K, et al
    The Effects of Antiglaucoma Ophthalmic Solutions on the Cornea Revealed by a Corneal Electrical Resistance Device.
    J Ocul Pharmacol Ther. 2021 Jan 13. doi: 10.1089/jop.2020.0077.
    PubMed     Abstract available


  101. EGUCHI H, Nishida K, Hotta F, Shimomura Y, et al
    In Vitro Antimicrobial Activity of Quinolones Against Major Bacterial Isolates from the Ocular Surface Bacterial Flora of Tertiary Hospital Patients in Japan.
    J Ocul Pharmacol Ther. 2021 Jan 4. doi: 10.1089/jop.2020.0091.
    PubMed     Abstract available


  102. GLICKMAN RD, Onorato M, Campos MM, O'Boyle MP, et al
    Intraocular Injection of HyStem Hydrogel Is Tolerated Well in the Rabbit Eye.
    J Ocul Pharmacol Ther. 2021;37:60-71.
    PubMed     Abstract available


  103. SHIN J, Rho CR, Hyon JY, Chung TY, et al
    A Randomized, Placebo-Controlled Phase II Clinical Trial of 0.01% or 0.02% Cyclosporin A with 3% Trehalose in Patients with Dry Eye Disease.
    J Ocul Pharmacol Ther. 2021;37:4-11.
    PubMed     Abstract available


  104. BOZKURT E, Muhafiz E, Yayla M, Cinar I, et al
    The Relationship of the Urotensin-2 Level in the Aqueous Humor with Systemic Diseases and Pupil Size: Comparative Study.
    J Ocul Pharmacol Ther. 2021;37:45-51.
    PubMed     Abstract available


    December 2020
  105. SHIRAI C, Matsuoka N, Nakazawa T
    Adherence and Persistence with First-Line Therapy and Compliance with Glaucoma Guidelines Using Japanese Health Care/Pharmacy Claims Database.
    J Ocul Pharmacol Ther. 2020 Dec 23. doi: 10.1089/jop.2020.0096.
    PubMed     Abstract available


  106. KAMIYA T, Omae T, Nakabayashi S, Takahashi K, et al
    Effect of Rho Kinase Inhibitor Ripasudil (K-115) on Isolated Porcine Retinal Arterioles.
    J Ocul Pharmacol Ther. 2020 Dec 22. doi: 10.1089/jop.2020.0082.
    PubMed     Abstract available


  107. SOMAYAJULU M, McClellan SA, Pitchaikannu A, Bessert D, et al
    Effects of Glycyrrhizin Treatment on Diabetic Cornea.
    J Ocul Pharmacol Ther. 2020 Dec 21. doi: 10.1089/jop.2020.0105.
    PubMed     Abstract available


  108. LUKE MC, Kozak D
    Regulating Generic Ophthalmologic Drug Bioequivalence-Envisioning Accessibility for Patients.
    J Ocul Pharmacol Ther. 2020 Dec 17. doi: 10.1089/jop.2020.0041.
    PubMed     Abstract available


  109. ALTUN A, Kanar HS, Aki SF, Arsan A, et al
    Effectiveness and Safety of Coadministration of Intravitreal Dexamethasone Implant and Silicone Oil Endotamponade for Proliferative Diabetic Retinopathy with Tractional Diabetic Macular Edema.
    J Ocul Pharmacol Ther. 2020 Dec 16. doi: 10.1089/jop.2020.0079.
    PubMed     Abstract available


  110. DINC E, Dursun O, Yilmaz G, Kurt AH, et al
    Evaluation of Anti-Inflammatory and Antiapoptotic Effects of Bone Marrow and Adipose-Derived Mesenchymal Stem Cells in Acute Alkaline Corneal Burn.
    J Ocul Pharmacol Ther. 2020 Dec 3. doi: 10.1089/jop.2020.0103.
    PubMed     Abstract available


  111. ALAGOZ N, Tellioglu A, Bektasoglu DL, Yasar T, et al
    Do We Conform with European Glaucoma Society Guidelines in the Medical Treatment of Primary Open-Angle Glaucoma/Ocular Hypertension? Data from a Real-Life Practice.
    J Ocul Pharmacol Ther. 2020;36:747-753.
    PubMed     Abstract available


    November 2020
  112. CUI W, Sun XY, Sun LP, Li J, et al
    Comparison of the Effect of Intravitreal Conbercept and Ranibizumab on Aqueous Humor Cytokines in Central Retinal Vein Occlusion-Related Macular Edema.
    J Ocul Pharmacol Ther. 2020 Nov 19. doi: 10.1089/jop.2020.0035.
    PubMed     Abstract available


  113. DUTESCU RM, Uthoff D, Panfil C, Schrage N, et al
    High-Frequency Application of Cationic Agents Containing Lubricant Eye Drops Causes Cumulative Corneal Toxicity in an Ex Vivo Eye Irritation Test Model.
    J Ocul Pharmacol Ther. 2020 Nov 11. doi: 10.1089/jop.2020.0043.
    PubMed     Abstract available


  114. KECIK D, Grabska-Liberek I, Jurowski P, Mrukwa-Kominek E, et al
    Stable Mydriasis After Intracameral Injection of a Combination of Mydriatics and Anesthetic During Cataract Surgery: A Real-Life, Multicenter Study.
    J Ocul Pharmacol Ther. 2020 Nov 4. doi: 10.1089/jop.2020.0001.
    PubMed     Abstract available


    October 2020
  115. QIN C, Wen S, Zhu S, Liu D, et al
    Are Poly(amidoamine) Dendrimers Safe for Ocular Applications? Toxicological Evaluation in Ocular Cells and Tissues.
    J Ocul Pharmacol Ther. 2020 Oct 29. doi: 10.1089/jop.2020.0078.
    PubMed     Abstract available


  116. FU D, Yu JY, Connell AR, Hookham MB, et al
    Effects of Modified Low-Density Lipoproteins and Fenofibrate on an Outer Blood-Retina Barrier Model: Implications for Diabetic Retinopathy.
    J Ocul Pharmacol Ther. 2020 Oct 27. doi: 10.1089/jop.2020.0068.
    PubMed     Abstract available


    September 2020
  117. MANDELL KJ, Clark D, Chu DS, Foster CS, et al
    Randomized Phase 2 Trial of Reproxalap, a Novel Reactive Aldehyde Species Inhibitor, in Patients with Noninfectious Anterior Uveitis: Model for Corticosteroid Replacement.
    J Ocul Pharmacol Ther. 2020 Sep 22. doi: 10.1089/jop.2020.0056.
    PubMed     Abstract available


    March 2020
  118. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2020;36:73-74.
    PubMed    


  119. LEE JH, Lee SC, Lee CS
    Comparison of Half-Time and Half-Irradiance Photodynamic Therapy in Nonresolving Central Serous Chorioretinopathy.
    J Ocul Pharmacol Ther. 2020;36:109-115.
    PubMed     Abstract available


  120. LI Y, Jin R, Li L, Hsu HH, et al
    Therapeutic Effect of Topical Adiponectin-Derived Short Peptides Compared with Globular Adiponectin in Experimental Dry Eye and Alkali Burn.
    J Ocul Pharmacol Ther. 2020;36:88-96.
    PubMed     Abstract available


    January 2020
  121. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2020;36:1-2.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Ophthalmology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: